Oncogenic MAP2K1 mutations in human epithelial tumors

Carcinogenesis

Volumn 33, Issue 5, 2012, Pages 956-961

  Choi, Young Lim ^a,b   Soda, Manabu ^a   Ueno, Toshihide ^a   Hamada, Toru ^a   Haruta, Hidenori ^a   Yamato, Azusa ^a   Fukumura, Kazutaka ^b   Ando, Mizuo ^b   Kawazu, Masahito ^b   Yamashita, Yoshihiro ^a   Mano, Hiroyuki ^a,b,c  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLUTAMINE; MITOGEN ACTIVATED PROTEIN 2 KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROLINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CELL DEATH; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCIRRHOUS GASTRIC CANCER; STOMACH CANCER;

EID: 84860469479     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs099     Document Type: Article

References (25)

1. Sebolt-Leopold, J.S. et al. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer, 4, 937-947.
2. Karnoub, A.E. et al. (2008) Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol., 9, 517-531.
3. Downward, J. (2008) Targeting RAS and PI3K in lung cancer. Nat. Med., 14, 1315-1316.
4. Rane, S.G. et al. (2000) Janus kinases: components of multiple signaling pathways. Oncogene, 19, 5662-5679.
5. Ishitani, T. et al. (1999) The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature, 399, 798-802.
6. Davies, H. et al. (2002) Mutations of the BRAF gene in human cancer. Nature, 417, 949-954.
7. American Cancer Society. (2008) Global Cancer Facts and Figures 2007. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts_and_Figures_2008.asp?from5fast (22 February 2012, date last accessed).
8. Soda, M. et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-566.
9. Kwak, E.L. et al. (2010) Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N. Engl. J. Med., 363, 1693-1703.
10. Flaherty, K.T. et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med., 363, 809-819.
11. Weinstein, I.B. et al. (2006) Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 3, 448-457.
12. Onishi, M. et al. (1996) Applications of retrovirus-mediated expression cloning. Exp. Hematol., 24, 324-329.
13. Chen, C.Y. et al. (2002) Peritoneal carcinomatosis and lymph node metastasis are prognostic indicators in patients with Borrmann type IV gastric carcinoma. Hepatogastroenterology, 49, 874-877.
14. Guilford, P. et al. (1998) E-cadherin germline mutations in familial gastric cancer. Nature, 392, 402-405.
15. Bottorff, D. et al. (1995) RAS signalling is abnormal in a c-raf1 MEK1 double mutant. Mol. Cell. Biol., 15, 5113-5122.
16. Marks, J.L. et al. (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res., 68, 5524-5528.
17. Yeh, T.C. et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res., 13, 1576-1583.
18. Estep, A.L. et al. (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE, 2, e1279.
19. Dentici, M.L. et al. (2009) Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations. Eur. J. Hum. Genet., 17, 733-740.
20. Pao, W. et al. (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol, 12, 175-180.
21. Bentivegna, S. et al. (2008) Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum. Mutat., 29, 441-450.
22. Tong, C. et al. (2003) Effects of MEK inhibitor U0126 on meiotic progression in mouse oocytes: microtuble organization, asymmetric division and metaphase II arrest. Cell Res., 13, 375-383.
23. Yamaguchi, H. et al. (1996) Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature, 384, 484-489.
24. Mansour, S.J. et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science, 265, 966-970.
25. Choi, Y.L. et al. (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med., 363, 1734-1739.